文献速递MDS 与骨髓增殖性肿瘤

原发性骨髓纤维化中的驱动突变与预后:Mayo-Careggi MPN联盟1,095例患者研究

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.
PubMed 文献 · Am J Hematol · 2017-12-18

在709例Mayo Clinic原发性骨髓纤维化患者中,1型/类CALR突变者生存期长于JAK2、2型/类CALR、MPL及三阴性突变者;多变量分析中,缺乏1型/类CALR、ASXL1/SRSF2突变及DIPSS-plus均预测较差生存;1型/类CALR可部分抵消高危分子突变的负面效应,该发现在386例外部队列中得到验证。

要点

  • 1型/类CALR突变者生存优于JAK2、2型/类CALR、MPL及三阴性状态。
  • 缺乏1型/类CALR、ASXL1/SRSF2突变及DIPSS-plus均独立预测较差生存。
  • 伴ASXL1/SRSF2突变者中,有1型/类CALR突变者生存更长。

核心结论

  • 原发性骨髓纤维化中1型/类CALR突变不仅预测更优生存,还部分修正高危分子突变的负面效应。

研究设计与样本

  • Mayo Clinic 709例原发性骨髓纤维化患者队列分析,并在386例佛罗伦萨Careggi医院外部队列中验证。

主要发现

  • 709例中467例(66%)为JAK2突变,112例(16%)为1型/类CALR,24例(3.4%)为2型/类CALR,38例(5.4%)为MPL突变,68例(10%)为三阴性。
  • 1型/类CALR生存长于JAK2(HR 2.6,95%CI 1.9-3.5)、2型/类CALR(HR 2.5,95%CI 1.4-4.5)、MPL(HR 1.8,95%CI 1.1-2.9)及三阴性(HR 2.4,95%CI 1.6-3.6)。
  • 非1型/类CALR各突变状态间生存相似(P = .41)。
  • 多变量分析中,缺乏1型/类CALR(P < .001;HR 2,95%CI 1.4-2.7)、ASXL1/SRSF2突变(P < .001;HR 1.9,95%CI 1.5-2.4)及DIPSS-plus(P < .001)均预测较差生存。
  • 210例ASXL1/SRSF2突变患者中,有1型/类CALR突变者生存长于无者(中位5.8年 vs 2.9年;P < .001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2013 discovery of calreticulin (CALR) mutations in myeloproliferative neoplasms was attended by their association with longer survival in primary myelofibrosis (PMF). Subsequent studies have suggested prognostic distinction between type 1/like and type 2/like CALR mutations and detrimental effect from triple-negative mutational status. Among 709 Mayo Clinic patients with PMF, 467 (66%) harbored JAK2, 112 (16%) CALR type 1/like, 24 (3.4%) CALR type 2/like, 38 (5.4%) MPL mutations and 68 (10%) were triple-negative. Survival was longer with type 1/like CALR, compared to JAK2 (HR 2.6, 95% CI 1.9-3.5), type 2/like CALR (HR 2.5, 95% CI 1.4-4.5), MPL (HR 1.8, 95% CI 1.1-2.9) and triple-negative mutational status (HR 2.4, 95% CI 1.6-3.6), but otherwise similar between the non-type 1/like CALR mutational states (P = .41). In multivariable analysis, the absence of type 1/like CALR (P < .001; HR 2, 95% CI 1.4-2.7), presence of ASXL1/SRSF2 mutations (P < .001; HR 1.9, 95% CI 1.5-2.4) and DIPSS-plus (P < .001) were each predictive of inferior survival. Furthermore, among 210 patients with ASXL1/SRSF2 mutations, survival was significantly longer in the presence vs. absence of type 1/like CALR mutations (median 5.8 vs. 2.9 years; P < .001). Triple-negative status did not disclose additional prognostic information for overall or leukemia-free survival. The observations regarding the prognostic distinction between CALR mutation variants were validated in an external cohort of 386 patients from the University of Florence Careggi hospital. We conclude that type 1/like CALR mutations in PMF not only predict superior survival, but also partially amend the detrimental effect of high molecular risk mutations.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Nicolosi M, Mudireddy M, et al. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2017. PMID: 29164670. doi:10.1002/ajh.24978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。